Details of the Drug

General Information of Drug (ID: DMD4381)

• Drug Name: Terbutaline
• Synonyms: Asthmasian; Brethaire; Brethine; Brican; Bricanyl; Bricar; Bricaril; Bricyn; Terbutalin; Terbutalina; Terbutalino; Terbutalinum; Terbutalina [DCIT]; Terbutaline sulfate; KWD 2019; Asthmasian (TN); Brethaire (TN); Brethine (TN); Bricanyl (TN); KWD-2019; Terbutaline (INN); Terbutaline [INN:BAN]; Terbutalino [INN-Spanish]; Terbutalinum [INN-Latin]; (+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol; (+-)-Terbutaline; 1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-(9CI); 5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL; 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol; 5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1], [2]

• Therapeutic Class: Bronchodilator Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 225.28
  Topological Polar Surface Area (xlogp); 0.9
  Rotatable Bond Count (rotbonds); 4
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1.7 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
  Bioavailability: The bioavailability of drug is 85% [3]
  Clearance: The clearance of drug is 3.0 mL/min/kg [5]
  Elimination: An oral dose of terbutaline is 40% eliminated in the urine after 72 hours [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.4 hours [7]
  Metabolism: The drug is metabolized via sulphated or glucuronidated [8]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.10968 micromolar/kg/day [9]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.75% [10]
  Vd: The volume of distribution (Vd) of drug is 1.6 L/kg [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 213 mg/mL [4]
• Chemical Identifiers:
  Formula: C12H19NO3
  IUPAC Name: 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
  Canonical SMILES: CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
  InChI: InChI=1S/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3
  InChIKey: XWTYSIMOBUGWOL-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5403
  ChEBI ID: CHEBI:9449
  CAS Number: 23031-25-6
  DrugBank ID: DB00871
  TTD ID: D0M8RC
  VARIDT ID: DR00971
  ACDINA ID: D00664

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Agonist	[11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[12]

Molecular Expression Atlas of This Drug

• The Studied Disease: Asthma
• ICD Disease Classification: CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	4.88E-01	-0.05	-0.12
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	7.10E-01	0.06	0.09
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	1.48E-01	6.33E-02	3.20E-01
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	1.74E-02	1.21E-01	4.40E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Terbutaline

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Budesonide	DMJIBAW	Minor	Increased risk of hypokalemia by the combination of Terbutaline and Budesonide.	Asthma [CA23]	[33]

Coadministration of a Drug Treating the Disease Different from Terbutaline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Terbutaline and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[34]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Ivosidenib.	Acute myeloid leukaemia [2A60]	[35]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Midostaurin.	Acute myeloid leukaemia [2A60]	[35]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Idarubicin.	Acute myeloid leukaemia [2A60]	[35]
Arn-509	DMT81LZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Arn-509.	Acute myeloid leukaemia [2A60]	[35]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Gilteritinib.	Acute myeloid leukaemia [2A60]	[35]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Oliceridine.	Acute pain [MG31]	[35]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Rivastigmine.	Alzheimer disease [8A20]	[36]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Terbutaline and Metronidazole.	Amoebiasis [1A36]	[37]
Ivabradine	DM0L594	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ivabradine.	Angina pectoris [BA40]	[35]
Bepridil	DM0RKS4	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Bepridil.	Angina pectoris [BA40]	[35]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Dronedarone.	Angina pectoris [BA40]	[35]
Bedaquiline	DM3906J	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[35]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Cilostazol.	Arterial occlusive disease [BD40]	[35]
Posaconazole	DMUL5EW	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Posaconazole.	Aspergillosis [1F20]	[35]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[35]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Terbutaline and Droxidopa.	Autonomic nervous system disorder [8D87]	[38]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[35]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Terbutaline and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[36]
Sparfloxacin	DMB4HCT	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Telithromycin	DMZ4P3A	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Telithromycin.	Bacterial infection [1A00-1C4Z]	[35]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Retigabine.	Behcet disease [4A62]	[35]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Eribulin.	Breast cancer [2C60-2C6Y]	[35]
Lapatinib	DM3BH1Y	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lapatinib.	Breast cancer [2C60-2C6Y]	[35]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Bosutinib.	Breast cancer [2C60-2C6Y]	[35]
Corticotropin	DMP9TWZ	Minor	Increased risk of hypokalemia by the combination of Terbutaline and Corticotropin.	Chronic kidney disease [GB61]	[33]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[35]
Levomilnacipran	DMV26S8	Moderate	Increased risk of rapid heart rate by the combination of Terbutaline and Levomilnacipran.	Chronic pain [MG30]	[39]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Terbutaline and Atracurium.	Corneal disease [9A76-9A78]	[40]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Terbutaline and Mivacurium.	Corneal disease [9A76-9A78]	[40]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Halothane.	Corneal disease [9A76-9A78]	[35]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Terbutaline and Pancuronium.	Corneal disease [9A76-9A78]	[40]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sevoflurane.	Corneal disease [9A76-9A78]	[35]
Probucol	DMVZQ2M	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Probucol.	Coronary atherosclerosis [BA80]	[35]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Pasireotide.	Cushing syndrome [5A70]	[35]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Osilodrostat.	Cushing syndrome [5A70]	[35]
Sertraline	DM0FB1J	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sertraline.	Depression [6A70-6A7Z]	[35]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Terbutaline and Selegiline.	Depression [6A70-6A7Z]	[34]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Terbutaline and Isocarboxazid.	Depression [6A70-6A7Z]	[34]
Milnacipran	DMBFE74	Moderate	Increased risk of rapid heart rate by the combination of Terbutaline and Milnacipran.	Depression [6A70-6A7Z]	[39]
Escitalopram	DMFK9HG	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Escitalopram.	Depression [6A70-6A7Z]	[35]
Desvenlafaxine	DMHD4PE	Moderate	Additive hypertensive effects by the combination of Terbutaline and Desvenlafaxine.	Depression [6A70-6A7Z]	[39]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Maprotiline.	Depression [6A70-6A7Z]	[35]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[35]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Deutetrabenazine.	Dystonic disorder [8A02]	[35]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Ingrezza.	Dystonic disorder [8A02]	[35]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Solifenacin.	Functional bladder disorder [GC50]	[35]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ketoconazole.	Fungal infection [1F29-1F2F]	[35]
Sunitinib	DMCBJSR	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[35]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Terbutaline and Procarbazine.	Hodgkin lymphoma [2B30]	[34]
Fostemsavir	DM50ILT	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[42]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Phenolphthalein.	Irritable bowel syndrome [DD91]	[36]
Crizotinib	DM4F29C	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Crizotinib.	Lung cancer [2C25]	[35]
Ceritinib	DMB920Z	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ceritinib.	Lung cancer [2C25]	[35]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Osimertinib.	Lung cancer [2C25]	[35]
Selpercatinib	DMZR15V	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Selpercatinib.	Lung cancer [2C25]	[35]
Lumefantrine	DM29GAD	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Lumefantrine.	Malaria [1F40-1F45]	[35]
Halofantrine	DMOMK1V	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Halofantrine.	Malaria [1F40-1F45]	[35]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Hydroxychloroquine.	Malaria [1F40-1F45]	[35]
Primaquine	DMWQ16I	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Primaquine.	Malaria [1F40-1F45]	[35]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[35]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[35]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Vemurafenib.	Melanoma [2C30]	[35]
LGX818	DMNQXV8	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and LGX818.	Melanoma [2C30]	[35]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Panobinostat.	Multiple myeloma [2A83]	[35]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Thalidomide.	Multiple myeloma [2A83]	[37]
Siponimod	DM2R86O	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Siponimod.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Fingolimod.	Multiple sclerosis [8A40]	[35]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Ozanimod.	Multiple sclerosis [8A40]	[43]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Romidepsin.	Mycosis fungoides [2B01]	[35]
Nilotinib	DM7HXWT	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Nilotinib.	Myeloproliferative neoplasm [2A20]	[35]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Dasatinib.	Myeloproliferative neoplasm [2A20]	[35]
Promethazine	DM6I5GR	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Promethazine.	Nausea/vomiting [MD90]	[35]
Granisetron	DMIUW25	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Granisetron.	Nausea/vomiting [MD90]	[35]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Ondansetron.	Nausea/vomiting [MD90]	[35]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Entrectinib.	Non-small cell lung cancer [2C25]	[35]
Sibutramine	DMFJTDI	Moderate	Additive hypertensive effects by the combination of Terbutaline and Sibutramine.	Obesity [5B80-5B81]	[44]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Levomethadyl Acetate.	Opioid use disorder [6C43]	[35]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Lofexidine.	Opioid use disorder [6C43]	[35]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Rucaparib.	Ovarian cancer [2C73]	[35]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Buprenorphine.	Pain [MG30-MG3Z]	[35]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Triclabendazole.	Parasitic worm infestation [1F90]	[35]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Terbutaline and Safinamide.	Parkinsonism [8A00]	[34]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Terbutaline and Rasagiline.	Parkinsonism [8A00]	[34]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Pimavanserin.	Parkinsonism [8A00]	[35]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Famotidine.	Peptic ulcer [DA61]	[37]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[45]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Lefamulin.	Pneumonia [CA40]	[35]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Degarelix.	Prostate cancer [2C82]	[35]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and ABIRATERONE.	Prostate cancer [2C82]	[35]
Enzalutamide	DMGL19D	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Enzalutamide.	Prostate cancer [2C82]	[35]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Relugolix.	Prostate cancer [2C82]	[35]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Bicalutamide.	Prostate cancer [2C82]	[35]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[35]
Ciclesonide	DM2NA4K	Minor	Increased risk of hypokalemia by the combination of Terbutaline and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[33]
Dexamethasone	DMMWZET	Minor	Increased risk of hypokalemia by the combination of Terbutaline and Dexamethasone.	Rheumatoid arthritis [FA20]	[33]
Quetiapine	DM1N62C	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Quetiapine.	Schizophrenia [6A20]	[35]
Mesoridazine	DM2ZGAN	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Mesoridazine.	Schizophrenia [6A20]	[35]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Aripiprazole.	Schizophrenia [6A20]	[37]
Iloperidone	DM6AUFY	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Iloperidone.	Schizophrenia [6A20]	[35]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Paliperidone.	Schizophrenia [6A20]	[35]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Amisulpride.	Schizophrenia [6A20]	[35]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Asenapine.	Schizophrenia [6A20]	[35]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Pimozide.	Schizophrenia [6A20]	[35]
Methylprednisolone	DM4BDON	Minor	Increased risk of hypokalemia by the combination of Terbutaline and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[33]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Terbutaline and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[36]
Vandetanib	DMRICNP	Major	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[35]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[35]
Doxorubicin	DMVP5YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[35]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Pitolisant.	Somnolence [MG42]	[35]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[35]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Terbutaline and Lenvatinib.	Thyroid cancer [2D10]	[35]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Cabozantinib.	Thyroid cancer [2D10]	[35]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Papaverine.	Tonus and reflex abnormality [MB47]	[46]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Terbutaline and Vecuronium.	Tonus and reflex abnormality [MB47]	[40]
Trimeprazine	DMEMV9D	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[41]
Fluticasone	DMGCSVF	Minor	Increased risk of hypokalemia by the combination of Terbutaline and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[33]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Procainamide.	Ventricular tachyarrhythmia [BC71]	[35]
Propafenone	DMPIBJK	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Propafenone.	Ventricular tachyarrhythmia [BC71]	[35]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Terbutaline and Flecainide.	Ventricular tachyarrhythmia [BC71]	[35]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Terbutaline and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[35]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Hydrochloric acid	E00015	313	Acidulant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Edetate disodium	E00186	8759	Complexing agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Water	E00035	962	Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Terbutaline Sulfate 2.5mg tablet	2.5mg	Tablet	Oral
Terbutaline Sulfate 5mg tablet	5mg	Tablet	Oral
Terbutaline Sulfate 1mg/ml injectable	1mg/ml	Injectable	Injection
Terbutaline 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Terbutaline 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 560).
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075877.
• [3] Summary of Product Characteristics: Galvus (vildagliptin) oral tablets
• [4] BDDCS applied to over 900 drugs
• [5] Nyberg L: Pharmacokinetic parameters of terbutaline in healthy man. An overview. Eur J Respir Dis Suppl. 1984;134:149-60.
• [6] Ripe E, Hornblad Y, Tegner K: Oral administration of terbutaline in asthmatic patients. Eur J Respir Dis Suppl. 1984;134:171-9.
• [7] Dailymed: Terbutaline Sulfate Oral Tablet
• [8] Fellner C: Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T. 2012 Sep;37(9):503-30.
• [9] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [10] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [11] Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11.
• [12] Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
• [13] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [14] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [15] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [16] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [17] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [18] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [19] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [20] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [21] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [22] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [23] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [24] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [25] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [26] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [27] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [28] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [29] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [30] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [31] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [32] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
• [33] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [34] Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
• [35] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [36] Canadian Pharmacists Association.
• [37] Cerner Multum, Inc. "Australian Product Information.".
• [38] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [39] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [40] Multum Information Services, Inc. Expert Review Panel.
• [41] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [42] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [43] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [44] Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
• [45] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [46] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]